ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Phase III Lung Cancer Trial Stopped Early Due to Significant Survival Improvement
April 29, 2020Regeneron and Sanofi announced the primary endpoint of overall survival (OS) was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo® (cemiplimab). -
Libtayo approved for CSCC in the EU, including through the NHS in the UK
July 04, 2019Sanofi and Regeneron have announced that the European Commission (EC) has granted conditional approval to Libtayo (cemiplimab) for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), a form of skin cancer, who cannot be -
Sanofi, Regeneron's Libtayo hits hot streak with EU green light, NICE backing
July 04, 2019Sanofi and Regeneron’s Libtayo is two for two in the last two days—with European officials, that is. -
Health Canada issues Notice of Compliance with Conditions (NOC/c) for Libtayo (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC)
April 12, 2019CSCC is the second most common skin cancer in Canadai. -
Regeneron's Libtayo is chugging along in skin cancer. Next stop? First-line lung
February 24, 2019Regeneron CEO Len Schleifer has called its brand-new cancer drug Libtayo “the engine that could.” And Wednesday, those wondering, “could what?” got a glimpse at what the PD-1 latecomer has done so far.
Pharma Sources Insight January 2025
